Search
for

    GlossarySetipiprant

    Setipiprant is an investigational oral medication that acts as a selective antagonist of the prostaglandin D2 receptor (DP2), which is implicated in hair loss, particularly androgenetic alopecia. By blocking this receptor, setipiprant aims to inhibit the signaling pathways that contribute to hair follicle miniaturization and hair thinning. Its relevance lies in its potential to promote hair regrowth and improve hair density in individuals experiencing hair loss, distinguishing it from other treatments that may target different biological mechanisms. Ongoing clinical trials are assessing its efficacy and safety in the context of hair restoration.

    Related Terms

    ๐Ÿ›’ Where to find Setipiprant

    Tracking 1 raw product by companies like Anageninc. View product ยป

    Learn

    5 / 801 results

      learn Pyrilutamide

      highly targeted anti-androgen that might have minimal systemic effects

      learn RU58841

      a potent but unapproved and potentially problematic topical anti-androgen

      learn Tofacitinib

      a JAK inhibitor for alopecia areata and other autoimmune conditions

    Research

    5 / 41 results

    Community Join

    5 / 45 results

      community Setipiprant trial results

      in Update  11 upvotes 6 years ago
      Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

      community SETIPIPRANT PGE2 GROUP BUY AND PIONEERING HAIR GROWTH

       6 upvotes 10 years ago
      The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.

      community Upcoming Setipiprant clinical trials hint at systemic daily dosage

       22 upvotes 9 years ago
      The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.